Skip to main content

Table 2 Treatment compliance and major toxicities

From: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study

Variables

Total (n = 201)

TP (n = 50)

TC(n = 151)

p

n (%)

n (%)

n (%)

Completed chemotherapy

184 (91.5)

43 (86)

141 (93.4)

0.139

Hematologic

72(35.8)

23 (46)

49 (32.5)

0.118

Leukopenia

68(33.8)

23 (46)

45(29.8)

0.054

Anemia

1( 0.5)

0(0)

1 (0.7)

1

Thrombocytopenia

4 ( 2.0)

2 (4)

2 (1.3)

0.259

Neutropenia

55 (27.4)

18 (36)

37(24.5)

0.162

Non-hematologic

45 (22.4)

19 (38)

26 (17.2)

0.004

Nauseau

17 ( 8.5)

7 (14)

10 (6.6)

0.139

Vomiting

9(4.5)

4(8)

5(3.3)

0.23

Esophagitis

8 ( 4.0)

4 (8)

4 (2.6)

0.108

Febrile neutropenia

7 ( 3.5)

5 (10)

2 (1.3)

0.011

Radiation pneumonitis

1 ( 0.5)

0 (0)

1 (0.7)

1

Hepatic dysfunction

1(0.5)

0(0)

1(0.7)

1